833 4-ASBESTOS

Biphasic Mesothelioma

Jump to

Biphasic Mesothelioma

Biphasic mesothelioma is a diagnosis that sits between two worlds. It contains both epithelioid and sarcomatoid cells, and neither component can be ignored.

This subtype accounts for approximately 12 to 25 percent of all mesothelioma cases. What makes it clinically distinct is not simply the presence of two cell types, but the fact that the sarcomatoid component drives disease behavior disproportionately to its percentage. A tumor that is 30 percent sarcomatoid does not behave like epithelioid disease with a small complication. It behaves significantly more aggressively than pure epithelioid mesothelioma across virtually every clinical measure.

Understanding the biphasic subtype — what it means, how it is diagnosed, and how treatment decisions are affected by the proportion of each component — is essential for patients and families navigating this diagnosis.

Learn how mesothelioma cell type affects your case and your options.

What Makes a Mesothelioma Biphasic

The 2021 World Health Organization classification of thoracic tumors established the diagnostic threshold for biphasic mesothelioma: both epithelioid and sarcomatoid components must each represent at least 10 percent of the tumor in adequately sampled tissue. This standard was clarified in the 2021 revision specifically because transitional mesothelioma — a cell type that had previously been classified separately — was reclassified as a sarcomatoid pattern. Many cases that would previously have been called "transitional" or mixed are now classified as either biphasic or sarcomatoid depending on the degree of spindle-cell features present.

The sarcomatoid component is responsible for the more aggressive clinical behavior of biphasic disease. Sarcomatoid cells proliferate faster, invade earlier, and respond less well to systemic therapy than epithelioid cells. In a biphasic tumor, the sarcomatoid cells set the pace of disease progression even when they represent a minority of the tumor volume.

This is why the percentage of each component matters clinically. A biphasic tumor that is 15 percent sarcomatoid and 85 percent epithelioid carries a substantially different prognosis than one that is 60 percent sarcomatoid and 40 percent epithelioid. Pathology reports should quantify each component, and treatment planning should take those percentages into account.

How Doctors Diagnose Biphasic Mesothelioma

Accurate diagnosis of biphasic mesothelioma requires adequate tissue. This is one of the most important and most frequently underappreciated aspects of the diagnosis.

Small needle biopsies often capture only one component of a biphasic tumor. A needle that samples the sarcomatoid area of a biphasic tumor may produce a report of sarcomatoid mesothelioma, when the full pathological picture would reveal a biphasic diagnosis. The reverse is also possible: sampling the epithelioid-predominant region of a tumor that contains substantial sarcomatoid areas may lead to classification as epithelioid disease and inform a treatment plan that significantly underestimates disease aggressiveness.

Surgical biopsy — ideally thoracoscopic or laparoscopic depending on disease site — generally provides better tissue samples for biphasic assessment. Pathologists need enough representative tissue to characterize both components, confirm their architectural patterns, and quantify their relative proportions.

Immunohistochemistry (IHC) is essential for both confirming mesothelioma and characterizing its components. The epithelioid component typically expresses calretinin, WT-1, CK5/6, and D2-40. The sarcomatoid component may show weaker expression of some of these markers, with broad-spectrum cytokeratins becoming especially important for confirming its mesothelial origin as opposed to a true sarcoma.

Molecular markers — loss of BAP1 expression, loss of MTAP expression, and homozygous deletion of CDKN2A detected by FISH — provide additional confirmation of malignancy in cases where IHC results are ambiguous. These markers are present across biphasic mesothelioma but tend to be more common in the sarcomatoid component.

A second opinion from a specialized mesothelioma pathologist is appropriate for any biphasic diagnosis. Interobserver variation in assessing the sarcomatoid component of biphasic tumors is well documented in the literature, and the stakes of misclassification are significant for both treatment planning and legal claims.

Staging

Mesothelioma staging uses the TNM system, with the most current standard being the 9th edition of the TNM Classification published in 2024. This edition revised the T component criteria, incorporating pleural thickness measurements and fissure involvement while removing several imaging descriptors that could not be reliably assessed. Stage groupings run from Stage I (T1N0) through Stage IV (any M1).

Staging for biphasic mesothelioma carries a fundamental caveat: the percentage of sarcomatoid component in the tumor is a stronger predictor of outcomes than TNM stage. Population data from the SEER database demonstrate that the hazard ratio for biphasic mesothelioma — compared to epithelioid disease — is approximately 1.62 after controlling for stage and other variables. This means a Stage I biphasic patient may face greater risks than a Stage II or even Stage III epithelioid patient.

This does not mean staging is irrelevant for biphasic patients. Stage affects clinical trial eligibility, surgical candidacy assessment, and the identification of distant metastases that would modify treatment options. But treatment planning should incorporate both stage and histological composition rather than relying on stage alone.

Treatment Options

Treatment decisions for biphasic mesothelioma depend heavily on what proportion of the tumor is sarcomatoid, the patient's performance status, disease stage, and where care is received.

Surgery. The surgical data for biphasic mesothelioma are less favorable than for epithelioid disease. In the SEER database analysis of 1,183 mesothelioma patients, cancer-directed surgery in biphasic mesothelioma carried a hazard ratio of 0.73 with a p-value of 0.19 — not statistically significant. Among surgical patients, the median survival was approximately 12 months, compared to 8 months for non-surgical patients — a modest difference that did not reach significance. Current guidelines from major oncology organizations recommend against radical surgery for patients whose biphasic tumors have substantial sarcomatoid components (generally above 50 percent).

For patients with low sarcomatoid percentage and otherwise favorable characteristics — adequate performance status, epithelioid-predominant biphasic disease, early-stage disease — lung-sparing surgery (pleurectomy/decortication) may be discussed at high-volume centers. The benefit is real in selected patients, but patient selection is critical and requires expert surgical evaluation.

Chemotherapy. Platinum-based chemotherapy combined with pemetrexed (the EMPHACIS regimen) remains the standard systemic approach for patients who are not candidates for immunotherapy. Response rates in biphasic disease are lower than in epithelioid mesothelioma, and survival benefit is more modest. However, chemotherapy remains an option for patients who do not respond well to or cannot tolerate immunotherapy.

Immunotherapy. The CheckMate 743 trial tested first-line nivolumab plus ipilimumab against platinum-pemetrexed chemotherapy in unresectable pleural mesothelioma. The trial's most striking results came from the non-epithelioid subgroup — a category that includes biphasic and sarcomatoid mesothelioma. In this subgroup, immunotherapy produced a median survival of 16.5 months compared to just 8.8 months with chemotherapy, a hazard ratio of 0.46. This represents one of the largest treatment effects observed in any mesothelioma subtype and has made dual checkpoint inhibitor therapy the preferred first-line approach for most biphasic patients.

The IND.227 trial, which tested pembrolizumab combined with platinum-pemetrexed chemotherapy, showed overall survival improvement with pembrolizumab addition (hazard ratio 0.79), with a larger benefit observed in the non-epithelioid subgroup on exploratory analysis.

The CONFIRM trial tested single-agent nivolumab in the second-line setting for relapsed mesothelioma and showed a meaningful survival benefit, suggesting continued immunotherapy activity even after progression.

Emerging Treatments. Mesothelin-targeted therapies, CAR T-cell approaches, and antibody-drug conjugates are active areas of investigation. Clinical trial enrollment is strongly encouraged for biphasic patients, particularly those with adequate performance status after first-line treatment.

Learn more about pleural mesothelioma treatment options and clinical evidence.

Prognosis

Biphasic mesothelioma carries intermediate prognosis between epithelioid and sarcomatoid disease, but the range of outcomes within the biphasic category is wide and depends substantially on the sarcomatoid percentage.

In population-based data from the SEER database, the overall median survival for biphasic mesothelioma is approximately 10 months. Five-year survival ranges from 0 to 8 percent depending on the population studied and treatment received. These figures predate the widespread adoption of immunotherapy and are likely improving for patients who receive current first-line regimens.

The most important prognostic variable within the biphasic subtype is the sarcomatoid percentage. Higher sarcomatoid proportion is associated with worse outcomes regardless of stage, treatment received, or other clinical variables. This is why accurate quantification of each component — not simply the biphasic diagnosis — is essential for prognosis and treatment planning.

Access to care at a high-volume mesothelioma center matters for biphasic patients just as it does for other subtypes. Evidence from the National Cancer Database documents a meaningful survival advantage for patients treated at academic centers compared to community facilities, even after adjustment for patient characteristics and disease stage.

Asbestos and Biphasic Mesothelioma

Biphasic mesothelioma is caused by asbestos exposure. The mechanism is the same as for other mesothelioma subtypes: asbestos fibers inhaled decades before diagnosis lodge in the pleural tissue, cause chronic inflammation and DNA damage, and ultimately trigger malignant transformation of the mesothelial cells. The latency period between initial exposure and diagnosis spans 20 to 50 years.

All six regulated types of asbestos — chrysotile, amosite, crocidolite, anthophyllite, tremolite, and actinolite — are capable of causing biphasic mesothelioma. The industries and occupations with the highest exposure risk are the same as for all mesothelioma subtypes: shipbuilding, power generation, construction trades, petrochemical refining, automotive manufacturing, steel production, and military service.

The specific genetic response to asbestos fiber damage — including which alterations occur in BAP1 and CDKN2A — may influence which histological subtype ultimately develops. Current research suggests that different patterns of molecular damage triggered by asbestos may favor different cell-type responses, though the precise mechanisms remain under active investigation.

Learn more about how exposure occurred in specific occupations. | Learn more about exposure through specific industries.

Legal Rights and Compensation

A biphasic mesothelioma diagnosis creates the same legal rights as any other mesothelioma subtype. The histological classification does not affect eligibility for any compensation pathway.

Asbestos Trust Fund Claims. More than 60 asbestos compensation trusts hold combined assets in excess of $30 billion, established when major asbestos manufacturers filed for bankruptcy under the weight of mesothelioma litigation. Claims are paper-based, do not require courtroom appearances, and are typically prioritized and expedited for mesothelioma patients. Many clients receive initial trust distributions within 30 days of filing. Most patients qualify for claims against multiple trusts because exposure typically involved products from more than one manufacturer.

Personal Injury Lawsuits. Companies that remain solvent can be sued directly for their role in causing asbestos exposure. Mesothelioma lawsuits typically settle before trial. For families who have lost a patient to biphasic mesothelioma, wrongful death claims follow the same framework and can be filed by surviving spouses, children, or dependents.

VA Disability Benefits. Veterans whose exposure occurred during military service may qualify for monthly tax-free disability compensation and VA healthcare coverage for mesothelioma treatment. Mesothelioma disability ratings are typically 100%. VA benefits can be pursued alongside trust fund claims and lawsuits without affecting eligibility for any of them.

Social Security Disability. Mesothelioma qualifies for the Social Security Administration's Compassionate Allowances program, which fast-tracks disability benefit approval to weeks rather than months. Approved SSDI also accelerates Medicare eligibility.

Our firm has recovered more than $400 million for asbestos victims and their families. We maintain a proprietary database of over 200,000 verified asbestos exposure sites, which allows us to identify the products and manufacturers responsible for a patient's exposure and match those to the trust funds and defendants available for claims.

Explore all your legal options. | Learn how we build cases other firms can't.

Take the Next Step

If you or a family member has been diagnosed with biphasic mesothelioma, the time to act is now. The aggressive biology of this disease means that legal action and treatment decisions need to happen in parallel, not sequentially. Trust fund claims can often be filed and resolved more quickly than lawsuits, and coordinating all compensation pathways together produces better outcomes than pursuing them one at a time.

The consultation is free. There's no obligation. You pay nothing unless we recover compensation for you.

Call 833-4-ASBESTOS (833-427-2378) or schedule your free consultation online.

References

  1. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608-622. doi:10.1016/j.jtho.2021.12.014

  2. Meyerhoff RR, Yang CJ, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32. doi:10.1016/j.jss.2015.01.043

  3. Cardillo G, Waller D, Tenconi S, Di Noia V, Ricciardi S. Malignant Pleural Mesothelioma: A 2025 Update. J Clin Med. 2025;14(3):1004. doi:10.3390/jcm14031004

  4. Nowak AK, Giroux DJ, Eisele M, et al. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024;19(9):1339-1351. doi:10.1016/j.jtho.2024.05.020

  5. Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457-466. doi:10.1016/S2213-2600(24)00028-2

  6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136

  7. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8

  8. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074

  9. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. doi:10.1016/S0140-6736(23)01148-4

  10. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised phase 3 trial. Lancet Oncol. 2021;22(11):1530-1540. doi:10.1016/S1470-2045(21)00471-X